Screening in Older People - When Not To
Existing guidelines recommend against screening for these tumours in individuals with limited life expectancy. Estimates put the cost to the U.S. healthcare system related to overdiagnosis at $1.2 billion annually.
The researchers assessed the prevalence of non-recommended screenings for breast and prostate cancers in the United States. Firas Abdollah, MD, of the Henry Ford Health System, Detroit, and colleagues analysed data from individuals who were 65 years or older and lived in the U.S. and who responded to the Behavioural Risk Factors Surveillance System survey in 2012.
See Also: ACS Guideline: Screening Mammography from 45
Of those 149,514 individuals — weighted to represent nearly 43.6 million people — there were 76,419 (51.1 percent) who had a mammography or prostate-specific antigen (PSA) test in the last year; 23,532 (30.8 percent) of those individuals had a life expectancy of less than 10 years. Those figures correspond to an overall rate of non-recommended screening of 15.7 percent (23,532 of 149,514 individuals), the researchers explain.
The results also showed that rates of non-recommended screening rates varied across the country, ranging from 11.6 percent in Colorado to 20.2 percent in Georgia. Interestingly, states with a high rate of non-recommended screening for breast cancer were likely to have a high rate of non-recommended screening for prostate cancer and vice versa.
Dr. Abdollah et al. note limitations to their study, including the possible overestimation of life expectancy and the inclusion of patients previously diagnosed, treated or observed for breast and prostate cancers.
“Efforts should be deployed to reduce non-recommended screening in states with a high rate of non-recommended screening. This effort may avoid significant harms to many individuals and improve the cost efficiency of screening initiatives,” the authors write.
Image credit: Flickr.com
Published on : Fri, 22 Jan 2016
With its customer driven design, amazing usability and freedom of movement, Agfa's DR 100s offers your facility a new force in mobile imaging. Combining a remarkably narrow width and light weight with a powerful generator and imaging processing, it puts...
The Next Evolution in Ultrasound, designed for high expectations ARIETTA 850 SE ultrasound platform responds to high expectations to answer the ever increasing demands of medical professionals. ARIETTA 850 SE’s fundamental performance has been...
Introducing a new chapter in ultrasound visualization technology. X-Porte was developed from the ground up to incorporate a breakthrough, proprietary beam-forming technology: XDI (Extreme Definition Imaging). This signal analysis algorithm shapes...
Remarkable image quality, right at the point of care. The Trident system revolutionizes breast tissue imaging by incorporating a micro-focused tube, unique specimen image processing algorithms and amorphous selenium direct digital detector. The...
Transform the breast imaging patient experience The SmartCurve system provides a curved compression surface that offers a more comfortable patient experience without compromising image quality, exam time, dose or workflow.1 The SmartCurve system is...